In this paper, we give an overview of articles on non-choline tracers for PET/CT for patients with prostate cancer and planning of radiotherapy guided by PET/CT.
Nineteen articles described 11C-Acetate PET/CT. Of 629 patients 483 (77%, 95% CI 74% - 80%) had positive 11C-Acetate PET/CT scans. Five articles described 18F-FACBC PET/CT. Of 174 patients 127 (73%, 95% CI 68% - 78%) had positive scans. Both tracers detected local lesions, lesions in regional lymph nodes, and distant organs. Ten articles described 18F-NaF PET/CT and found that 1289 of 3918 patients (33%) had positive reactive lesions in bones. PET/CT scan can guide external beam radiotherapy (EBRT) planning for patients with loco-regional prostate cancer. In six studies with 178 patients with localized prostate cancer, PET/CT pointed out dominant intraprostatic lesions (DIL). Oncologists gave the patients EBRT to the whole prostate and a simultaneously integrated boost to the DIL. Four studies with 254 patients described planning of EBRT for patients with PET-positive lymph nodes. During follow-up, 15 of 29 node-positive patients remained in remission for median 28 months (range 14 to 50 months). Most articles described 11C- and 18F-Choline as PET/CT tracers. In addition, 11C-Acetate and 18F-FACBC may be useful tracers. Planning of radiotherapy for localized prostate cancer guided by MRI or PET/CT is an investigational method. Current clinical controlled trials of the method evaluate whether it may improve overall survival.
Von Eyben FE, Kairemo K, Kiljunen T, Joensuu T. Are you the author?
Center of Tobacco Control Research, Birkevej 17, DK-5230 Odense M, Denmark.
Reference: Curr Radiopharm. 2015 Mar 16. Epub ahead of print.